| Ytd | -22.86% | |
| 1y | -37.86% |
| Open | 0.85 | Prev Close | 0.84 | Low | 0.83 | High | 0.93 | Mkt Cap | 25.02M |
| Vol | 591.27K | Avg Vol | 823.58K | EPS | -1.77 | P/E | -0.51 | Forward P/E | N/A |
| Beta | 1.35 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 0.99 | 200-d Avg | 1.25 | 1yr Est | 0.00 |
AUSTIN, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (
Rein Therapeutics Inc. (RNTX) Shareholder/Analyst Call Prepared Remarks Transcript
Twilio Inc (NYSE: TWLO) reported strong Q1 results and raised future sales guidance above estimates,